Premium
Smokeless tobacco extract alters gene expression in human dermal fibroblasts
Author(s) -
Malpass Gloria E.,
Prasad G. L.,
Howlett Allyn C.
Publication year - 2011
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.25.1_supplement.1090.12
Subject(s) - smokeless tobacco , nicotine , gene expression , cancer research , medicine , biology , gene , genetics , tobacco use , environmental health , population
Information on the cellular responses to smokeless tobacco products is very limited. Since skin is the first barrier of defense against wound and disease, and smokeless tobacco is in direct contact with oral cavity skin, this study focused on the effects of smokeless tobacco extract (STE) on biomarkers for signal transduction pathways in normal adult human dermal fibroblasts (HDFa). Gene expression (PCR) array analyses showed that 1% STE from 2S3 reference smokeless tobacco altered levels of several genes including: early growth response 1 (egr1), heat shock factor 1 (hsf1), v‐myc, tumor suppressor p53 (tp53), bone morphogenetic protein 4 (bmp4), cellular retinol binding protein 1 (rbp1), and transferrin receptor (p90, CD71) (tfrc). Increases in egr1, hsf1, bmp4 and tfrc occurred within 24 hrs of treatment, and in some cases, gene expression declined below control levels at 48 hrs. Levels of tp53 were reduced between 12 and 48 hrs. Future studies will address the changes in gene expression in response to tobacco smoke and smokeless tobacco for identifying biomarkers that predict harm from tobacco usage and assessing the relative risk of tobacco products. GEM is a RJR Leon Golberg Fellow.